The US Food and Drug
Administration (FDA) has approved
Tanzeum (albiglutide) subcutaneous
injection to improve glycemic
control, along with diet and
exercise, in adults with type 2
diabetes.
As well as imposing a Boxed
Warning on the product, the FDA
is requiring three post-marketing
surveillance studies to assess
paediatric dosing, efficacy and
safety, the risk of medullary thyroid
carcinoma in all patients over a
15 year period and cardiovascular
outcomes for patients with a high
baseline risk of cardiovascular
disease.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Apr 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.